Podcasts

Listen to the latest Hemonc news
from international experts

Advancing immunotherapy for solid tumors

Immunotherapy has the potential to treat all types of cancer, making it a highly lucrative area of research. Since the first FDA-approved immunotherapy for bladder cancer in 1990, the Bacillus Calmette-Guérin cancer vaccine, many more agents have arrived on the scene. A challenge in this field is not only finding the right therapeutic targets and optimizing efficacy, but also managing the immune-related side effects. In this podcast, our experts explore the use of immunotherapies in solid tumors.

James Spicer, FCRP, PhD, MRCP, MBBS, from Guy’s and St Thomas’ NHS Foundation Trust, London, UK, Michael Pishvaian, MD, PhD, from Georgetown University, Washington, WA, Marina Garassino, MD, from the National Cancer Institute of Milan, Milan, Italy, Barbara Burtness, MD, from Yale School of Medicine, New Haven, CT, Thomas Gajewski, MD, PhD, from the University of Chicago Comprehensive Cancer Center, Chicago, IL, Michel Sadelain, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, and Hans Hammer, MD, PhD, from the University of Texas Southwestern Medical Center, TX, USA, discuss a range of topics, including recent advancements, molecular targets, the current and future landscapes of immunotherapy, including CAR T-cells, as well as some of the challenges associated with patient selection and the immunotherapeutic treatment of solid tumors. All interviews were recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Date: 23rd November 2018